This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing KOMET-001 Phase 1b/2 study of Ziftomenib monotherapy in NPM1-mutant R/R AML presented at the ASCO Conference.

Ticker(s): KURA

Who's the expert?

Institution: Yale University

  • Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, Firm Chief of the Duffy Hematology Firm at Yale-New Haven Hospital and an Assistant Professor of Medicine (Medical Oncology and Hematology) at Yale University School of Medicine
  • Received his medical degree from Hannover Medical School in Hannover, Germany and completed residency training at Yale School of Medicine where I also served as chief medical resident
  • Received his medical degree from Hannover Medical School in Hannover, Germany and completed residency training at Yale School of Medicine where I also served as chief medical resident
  • Received the ASCO Conquer Cancer Foundation Young Investigator Award, the ASH HONORS Award, the Leukemia & Lymphoma Society Translational Research Program Award and several ASH Abstract Achievement Awards
  • Manages 500 patients with acute myeloid Leukemia 

Interview Goal
This conversation will focus on the recent ASCO 2025 data on the KOMET-001 Phase 1b/2 study of Ziftomenib monotherapy in NPM1-mutant R/R AML; meaningful update for KURA & SNDX to better understand how the utilization of these two therapies will shake out in this population.

Are You Interested In These Questions?

Slingshot Insights Explained
1Day Left to Join Project
Call Date
Jun 06, 2025
Call Time
03:00 PM EDT
Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.